title: Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
authors.affiliation: World Health Organization.
authors.forename: R
authors.initials: R
authors.lastname: Gupta
authors.forename: M C
authors.initials: MC
authors.lastname: Raviglione
authors.forename: M A
authors.initials: MA
authors.lastname: Espinal
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use*; D006078:Government Programs / Q000639:trends*; D006801:Humans; D007391:International Cooperation; D007538:Isoniazid / Q000627:therapeutic use*; D009313:National Health Programs / Q000639:trends*; D017410:Practice Guidelines as Topic; D012293:Rifampin / Q000627:therapeutic use*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014944:World Health Organization
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin